An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

All participants also received standard care for MASH. Participants got two liver biopsies to help evaluate the effects of semaglutide. About 56% of participants had type 2 diabetes, and about 73% ...

Semaglutide shows promise in MASH treatment, achieving significant MASH resolution and fibrosis improvement in the ESSENCE trial. Tolerability issues and insurance coverage challenges lead to 20% ...

Altimmune nears a key MASH trial readout, with strong market potential and new liver and alcohol studies supporting growth.

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH. Patients also saw improvements in weight, blood sugar, and insulin resistance. Experts say ...